CollPlant Biotechnologies (CollPlant Biotechnologies) COGS-to-Revenue : 5.56 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies COGS-to-Revenue?

CollPlant Biotechnologies's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.55 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.10 Mil.

CollPlant Biotechnologies's COGS to Revenue for the three months ended in Mar. 2024 was 5.56.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CollPlant Biotechnologies's Gross Margin % for the three months ended in Mar. 2024 was -456.12%.

CollPlant Biotechnologies COGS-to-Revenue Historical Data

The historical data trend for CollPlant Biotechnologies's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies COGS-to-Revenue Chart

CollPlant Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.81

0.49

0.13

1.34

0.18

CollPlant Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.75	0.06	6.47	2.59	5.56

CollPlant Biotechnologies COGS-to-Revenue Calculation

CollPlant Biotechnologies's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.991	/	10.959
	=	0.18

CollPlant Biotechnologies's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.545	/	0.098
	=	5.56

CollPlant Biotechnologies (NAS:CLGN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CollPlant Biotechnologies's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.545 / 0.098
	=	-456.12 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

CollPlant Biotechnologies COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CollPlant Biotechnologies (CollPlant Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

CPT:Germany

Address

4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104

Website

https://www.collplant.com

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.